A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

Thursday November 28th, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

Monday October 21st, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and the American biotech company, Zhittya Genesis Medicine (Zhittya), have successfully accomplished a tech transfer. 3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer […]

3P Biopharmaceuticals receives FDA approval

Wednesday September 18th, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]

3P Biopharmaceuticals_Betalutin

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

Wednesday June 26th, 2019 | General

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment. The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. 3P and Nordic Nanovector started their […]

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

Thursday June 6th, 2019 | General

The arrangement covers process transfer, process development and GMP manufacture of Affibody’s candidate 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody. […]

Large-scale manufacturing process for Strangvac now secured

Tuesday April 2nd, 2019 | General

We are so glad to be part of such an exciting project with the Swedish company INTERVACC, who we are working with on manufacturing of Strangvac® including the large-scale production of the vaccine against equine strangles. The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, secured large-scale production of the […]